[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371035-105":59,"doc-detail-371035-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","germline-pathogenic-variants-detected-by-genminetop-insight-from-a-nationwide-tumornormal-paired-comprehensive-genomic-profiling-test-article-open","Germline pathogenic variants detected by GenMineTOP: insight from a nationwide tumor/normal paired comprehensive genomic proﬁling test - article open","","Comprehensive genomic proﬁling (CGP) provides individualized tumor or tumor/normal genomic profiles to expand treatment options, yet tumor-only testing in Japan leaves presumed germline pathogenic variants (GPVs) incompletely validated. Paired tumor/normal analysis separates somatic from germline variants and supports diagnosis without confirmatory testing. GenMineTOP, covered by Japan’s national health insurance since August 2023, analyzes paired samples and reports GPVs in 40 genes. Among 1356 solid tumor patients tested from August 2023 to July 2024 in C-CAT, GPVs were detected in 73 patients (5.4%), with 38.2% classiﬁed as off-tumor.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/germline-pathogenic-variants-detected-by-genminetop-insight-from-a-nationwide-tumornormal-paired-comprehensive-genomic-profiling-test-article-open/371035/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/germline-pathogenic-variants-detected-by-genminetop-insight-from-a-nationwide-tumornormal-paired-comprehensive-genomic-profiling-test-article-open/371035.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the role of comprehensive genomic profiling (CGP) in this study?","Question",{"text":112,"@type":113},"CGP generates individualized genomic profiles of tumors or tumor/normal tissues to guide therapeutic options. It can also reveal germline pathogenic variants (GPVs) associated with hereditary cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are confirmatory tests needed for presumed GPVs in tumor-only testing?",{"text":117,"@type":113},"Tumor-only panels cannot reliably determine whether pathogenic variants suspected to be germline-derived are truly germline-derived based on medical history, variant allele frequency, and germline conversion rates. Germline confirmatory testing is required to confirm true GPVs.",{"name":119,"@type":110,"acceptedAnswer":120},"How does GenMineTOP differ from tumor-only approaches?",{"text":121,"@type":113},"GenMineTOP uses paired tumor/normal samples to detect GPVs without the need for confirmatory tests, enabling differentiation between somatic and germline variants. It reports GPVs in 40 genes and was covered by national health insurance in Japan starting August 2023.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371035,1790443713,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/jhg](www.nature.com/jhg)  \nARTICLE OPEN   \nGermline pathogenic variants detected by GenMineTOP: insight from a nationwide tumor/normal paired comprehensive genomic proﬁling test, in Japan  \nEri Habano 1, Miho Ogawa2, Kousuke Watanabe2, Nana Akiyama3, Hyangri Chang3, Mirei Ka 1, Aya Shinozaki-Ushiku 1, Masahiko Tanabe4, Masakazu Akahori5, Toshimitsu Ichijo5, Shuichi Tsutsumi6, Kenji Tatsuno6, Hiroyuki Aburatani 6, Hidenori Kage7 and Katsutoshi Oda1 ✉  \n© The Author(s) 2025  \n\n| | Comprehensive genomic proﬁling (CGP) expands treatment options for solid tumor patients and identiﬁes hereditary cancers. However, in Japan, conﬁrmatory tests have been conducted in only 31.6% of patients with presumed germline pathogenic variants (GPVs) detected through tumor-only testing. Paired tumor-normal analysis enables differentiation between somatic and germline variants. GenMineTOP, covered by Japan’s national health insurance since August 2023, analyzes paired samples and reports GPVs in 40 genes. This study provides an initial characterization of GPVs based on clinical ﬁndings collected during the ﬁrst year of GenMineTOP implementation. We analyzed 1356 solid tumor patients who underwent GenMineTOP testing in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database between August 2023 and July 2024, focusing on GPV detection rates, gene distribution, and comparisons with other CGP tests. Among the analyzed cancer types, GenMineTOP had a higher proportion of CNS/brain, soft tissue, bone, and head and neck cancers compared to other CGP tests. GPVs were detected in 73 patients (5.4%), with 38.2% classiﬁed as off-tumor. HR-related GPVs (ATM, BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D) were found in both males (median age: 69) and females (median age: 54) . Among males, 57.9% were aged 65 or older. GPVs may be detected in any cancer patients, including those with off-tumor ﬁndings, particularly in older male patients, especially in HR-related genes. These ﬁndings support the use of paired CGP to improve the diagnosis of hereditary cancers that could otherwise remain | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | undetected. |  |\n|  |  |  |\n|  |  |  |\n|  | Journal of Human Genetics (2026) 71:1–11; [https://doi.org/10.1038/s10038-025-01389-z](https://doi.org/10.1038/s10038-025-01389-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nComprehensive genomic proﬁling (CGP) creates individual genomic proﬁles of tumors or tumor/normal tissues to explore therapeutic options. The primary objective of CGP testing is to guide patient treatment; however, it also has the potential to reveal the presence of germline pathogenic variants (GPVs) . Here, GPVs are deﬁned as germline-derived pathogenic variants in genes associated with autosomal dominant hereditary cancers. In Japan, based on the ACMG SF v3.2 [1], the Kosugi Group List designates 53 genes for the disclosure of secondary ﬁndings (Supplementary Table 1). This list includes genes deemed clinically actionable when GPVs are detected through CGP testing or other comprehensive genetic analyses.  \nIn tumor-only panels, it is not possible to determine whether pathogenic variants, suspected to be of germline origin based on medical history, the Variant Allele Frequency (VAF) values and gene-speciﬁc germline conversion rates, are truly germlinederived. To conﬁrm whether a presumed GPV is a true GPV, germline conﬁrmatory testing (hereafter referred to as  \n‘conﬁrmatory tests’) is necessary. In contrast, tumor/normal paired panels can detect GPVs without the need for conﬁrmatory tests. Reports from international studies indicate that the detection rate of GPVs through CGP ranges from 4.3% to 17.5% [2–8] .  \nIdentifying hereditary cancers not only beneﬁts the affected individual but also facilitates health management for their relatives [3, 7, 9] .  \nAs of November 2024, ﬁv","cbCaiogK7lQqCds2","https://ap.wps.com/l/cbCaiogK7lQqCds2","pdf",3267086,11,"English","# Introduction\n## CGP goals and germline pathogenic variant definition\n## Need for confirmatory testing in tumor-only panels\n## Clinical use of CGP types in Japan and dataset characteristics","[{\"question\":\"What is the role of comprehensive genomic profiling (CGP) in this study?\",\"answer\":\"CGP generates individualized genomic profiles of tumors or tumor/normal tissues to guide therapeutic options. It can also reveal germline pathogenic variants (GPVs) associated with hereditary cancers.\"},{\"question\":\"Why are confirmatory tests needed for presumed GPVs in tumor-only testing?\",\"answer\":\"Tumor-only panels cannot reliably determine whether pathogenic variants suspected to be germline-derived are truly germline-derived based on medical history, variant allele frequency, and germline conversion rates. Germline confirmatory testing is required to confirm true GPVs.\"},{\"question\":\"How does GenMineTOP differ from tumor-only approaches?\",\"answer\":\"GenMineTOP uses paired tumor/normal samples to detect GPVs without the need for confirmatory tests, enabling differentiation between somatic and germline variants. It reports GPVs in 40 genes and was covered by national health insurance in Japan starting August 2023.\"}]","Germline pathogenic variants detected by GenMineTOP: insight from a nationwide tumor/normal paired comprehensive genomic proﬁling test - article open | PDF",1790191087,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac74648c7b0c434488f8724bb593354e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90087f12d4a44e8f91be93b6ddfe8eab.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20f1f368fc51a3c587ca9b2539706ed0.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4fb7513a4723a97c28e196023ff8ab3.webp",980,1301]